Nazartinib

Nazartinib is an oral, irreversible, third-generation, mutation-selective epidermal growth factor receptor (EGFR) inhibitor with potential anti-tumor activity. EGF816 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells.

• Supplier: Alfa Cytology
• Product #: BC0412